Last reviewed · How we verify
UV1 vaccine
At a glance
| Generic name | UV1 vaccine |
|---|---|
| Also known as | UV1 |
| Sponsor | Ultimovacs ASA |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma (PHASE2)
- Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma (PHASE1, PHASE2)
- A Phase I/IIa Study of UV1 Vaccination in Patients With Non Small Cell Lung Cancer. (PHASE1, PHASE2)
- A Phase I/IIa Study of UV1 Vaccine in Patients With Prostate Cancer (PHASE1, PHASE2)
- UV1 Vaccine With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma (PHASE1)
- Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma (PHASE2)
- Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer (PHASE2)
- Tolerability and Efficacy of UV1 Vaccine in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Planned for First-line Treatment With Pembrolizumab (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- UV1 vaccine CI brief — competitive landscape report
- UV1 vaccine updates RSS · CI watch RSS
- Ultimovacs ASA portfolio CI